>>> US Gapping up

Gapping up In reaction to strong earnings/guidance: SYNA +20.6%, (also acquires Renesas SP Drivers; co will pay a purchase price of ~JPY48.5B ($475 mln) for 100% of Renesas SP Drivers, based on JPY52.5B ($515 mln) enterprise value. The acquisition will be immediately accretive to Synaptics' non-GAAP EPS), ULTA +11.6%, RMBS +7.2%, (also signs comprehensive license agreement with Qualcomm (QCOM)) HRB +3.8%, SPWH +2.1% 

Select metals/mining stocks trading higher: AUY +1.1%, AG +0.8%, NEM +0.5%.

Other news: NAVB +8.9% (Lymphoseek injection demonstrates preferential accumulation in tumor-positive sentinel lymph nodes in post-hoc analysis), OSUR +7.2% (announces new co-promotion agreement for OraQuick HCV rapid antibody test), PTLA +7% (announces positive Phase 2 data with FDA-designated breakthrough therapy Andexanet Alfa and Enoxaparin), SPEX +6.7% (and Charter Communications (CHTR) file joint stipulation of dismissal), END +5% (cont strength following guidance), PSEC +4.9% (announces no restatement of historical financial statements based on discussions with the Office of the Chief Accountant of the SEC ), AMRN +3.3% (announces publication of case study results describing reductions in multiple lipid parameters for individual hyperlipidemic patients switched to Vascepa), INFY +2.9% (still checking), ITRN +2.8% (thinly traded, still checking), PBR +2.4% (still checking), GHDX +2.2% (announces positive topline results of second large, independent validation study of Oncotype DX in DCIS breast cancer), CRDC +2% (announced completion of laparoscopic appendectomy procedure with virtually no perceptible scar), NKTR +1.6% (FDA advisory committee to discuss peripherally-acting opioid receptor antagonists - halted), BSX +0.9% (announces clinical study results demonstrate therapeutics advantages of the Boston Scientific Vercise DBS System for patients with Parkinson's disease), BLRX +0.9% (receives notice of allowance for US Patent covering novel treatment for celiac disease ), PGNX +0.8% (FDA advisory committee to consider and provide recommendations regarding peripherally-acting opioid receptor antagonists - halted).

Analyst comments: ANGI +3.6% (upgraded to Buy at Wunderlich), MU +2.7% (upgraded to Buy from Underperform at BofA/Merrill), MRVL +1.1% (upgraded to Buy from Neutral at Nomura), AMZN +1% (added to Conviction Buy list at Goldman), SNDK +1% (upgraded to Buy from Underperform at BofA/Merrill), DSX +1% (upgraded to Equal Weight from Underweight at Barclays)

WSJ : Hedge-Fund World's One-Man Wealth Machine

Hedge-Fund World's One-Man Wealth Machine

David Abrams Built His Fortune Effectively Going It Alone

In the Back Bay neighborhood of Boston, one man is building a moneymaking machine that rivals some of the hedge-fund industry's biggest names.
Calls to his office go unreturned even from those eager to fork over eight-figure sums, potential investors say. One industry veteran referred to him as "a unicorn," as few people have ever seen him.

The hedge-fund manager, David Abrams, has personally become a billionaire, and earned billions more for his wealthy investors, over the past five years running what is effectively a one-man shop, according to company and investor documents reviewed by The Wall Street Journal and people who have worked with him. His firm, Abrams Capital Management LP, manages nearly $8 billion across three funds and is discussing raising money for a fourth fund that could help push its assets past $10 billion.
In an era of star investors who appear regularly on television and talk up their ideas at hyped confabs, Mr. Abrams, 53 years old, has never spoken at an event open to the public.
"He probably would have preferred you not find him," said Roger Brown, president of Berklee College of Music, where Mr. Abrams is a trustee.
Abrams Capital's main funds have posted an average annualized return of about 15% since its founding in 1999, documents show, nearly double the average for hedge funds tracked by HFR Inc. and triple the S&P 500 index, including dividends.

The firm invests in a relatively small number of beaten-down companies at a time, mostly through stocks at present, though it has also dipped into some of the more-talked-about fixed-income deals of recent years, including the unwinding of bankrupt Enron Corp. Among its recent stockholdings have been bookseller Barnes & Noble Inc., retailer J.C. Penney Co. and money-transfer firm Western Union Co., securities filings and investor documents show.
Mr. Abrams also is among the small group of investors that has taken a big bet on government-controlled mortgage companies Fannie Mae and Freddie Mac, wagering that the Obama administration's plan to wind down and replace the entities will fail, according to investor documents.
The firm employs three analysts and a small back-office staff, but Mr. Abrams approves all trades personally, according to people that have worked with him. Other firms of comparable assets can have hundreds of employees.
He also built his fortune with the equivalent of one hand tied behind his back: His firm uses no leverage, or borrowed money, and often sits on billions in cash. It currently holds about 40% of its $8 billion under management in cash, investor updates show.
Mr. Abrams got his start in 1988 at Baupost Group LLC, also based in Boston. Run by Seth Klarman, Baupost is one of the world's largest hedge-fund firms, with $27 billion under management.
The two remain friends, and Mr. Klarman's personal foundation has put money into Abrams Capital's funds. Mr. Klarman described his protégé as "smart as a whip."
"He loves a good puzzle and a good treasure hunt," Mr. Klarman said.
People who have worked with him said the University of Pennsylvania graduate who majored in history is introverted and cerebral. The son of a stockbroker and psychotherapist and a father of two, he is an avid follower of jazz music and fan of the band Earth, Wind and Fire.
Like Mr. Klarman, Mr. Abrams is known to be patient to the extreme. He will sit on a static portfolio for months without making a move.
Investors in the firm, including institutions like Brandeis University, with an endowment of about $700 million, sometimes get scant information. Mr. Abrams's most recent quarterly letter consists of just six paragraphs, one of which is a single sentence.
"He's not going to waste a nanosecond to impress you, or convince you, or argue with you," said Mr. Brown of Berklee. "He knows what he thinks and if you ask him, he'll tell you. If you don't, he might just sit there in silence."
Mr. Abrams likely collected more than $400 million last year on the back of a 23% return for one of his main funds, according to Journal calculations based on his fees, performance and his personal investment in the firm. He doesn't appear on lists of top-paid hedge-fund managers because his performance figures are so closely guarded, but his estimated compensation last year would have put him ahead of David Einhorn, Daniel Och and even Mr. Klarman, according to industry publication Institutional Investor's Alpha.
A portion of his earnings came from a private-equity-style vehicle, which doesn't pay out gains until it is unwound, and a handful of firm executives may have shared a small slice of his payday. The hedge funds were up an additional 2% in the first quarter, investor documents show.
As a side gig, in 2007 Mr. Abrams was part of a group that bought a 20% stake in the National Football League's Oakland Raiders. Forbes estimates the team's worth at $825 million, the NFL's least valuable team. Before the purchase, he wasn't a big football fan but views the team as a distressed investment, a person close to him said. The person said Mr. Abrams prefers to play squash at the University Club of Boston.

>>> Japan Tobacco Inc Acquires Leading E-cigarette Brand E-Lites; financial term

Japan Tobacco Inc Acquires Leading E-cigarette Brand E-Lites; financial terms not disclosed
- Announced today that it has concluded an agreement to acquire all outstanding shares of Zandera Ltd. ("Zandera"), a leader in e-cigarettes and best known for its E-Lites brand. Founded in 2009, Zandera sells the most recognized range of high quality rechargeable and ready-to-use e-cigarettes in the United Kingdom. 
- The executive management team of Zandera will remain with the JT Group post-acquisition in order to leverage upon their extensive knowledge and experience of the e-cigarette industry, their understanding of the product, technology and regulatory landscape. 
- This transaction will be funded by the Group's existing cash and loan facilities and is expected to have a minor effect on the Group's consolidated performance and cash flows for the fiscal year 2014. JT expects to complete the acquisition in the second quarter of the fiscal year 2014 following regulatory clearance.

>>> US Early premarket gappers

Early premarket gappers

Gapping up: SYNA +18%, SYNA +18%, ULTA +9.3%, RMBS +8%, SPEX +6.7%, NAVB +6.1%, TEDU +6%, AVNR +5.5%, PSEC +5.3%, INFY +3%, MU +2.7%, SPWH +2.1%, CRDC +2%, AG +0.8%, BSX +0.5%

Gapping down: OREX -15.9%, PVA -5%, ACHN -3.7%, RCPT -3.7%, EXC -3.1%, STAY -2%, IDRA -2%, BNNY -2%, ING -1.8%, UBS -1.8%, SAN -1.6%, UNFI -1.5%, OXM -1.3%, BA -1.1%, DDD -1.1%, DAL -1%, JD -0.9%, DB -0.9%, BCS -0.9%

>>> Klarman’s Baupost to Gain More Than $900 Million on Idenix, have a look to

names he has in its portfolio :
MICRON TECH MU US
VIASAT INC VSAT US
THERAVANCE THRX US
IDENIX PHARM IDIX US
CHENIERE ENERGY LNG US
BP PLC-ADR BP US
PBF ENERGY INC-A PBF US
KERYX BIOPHARM KERX US
NOVAGOLD RES NG US
CHIPMOS TECH IMOS US
CITIGROUP-CW19 C/WS/A US
RF MICRO DEVICES RFMD US
TRIQUINT SEMICON TQNT US
KINDRED BIOSCIEN KIN US
SYNERON MEDICAL ELOS US
ALLIANCE ONE INT AOI US
AMERICAN IN-CW21 AIG/WS US
NOVACOPPER INC NCQ US
AVEO PHARMACEUTI AVEO US
ALON USA PARTNER ALDW US

NY POst : Move to Switzerland to dodge IRS may give Walgreen blues

If Walgreen wants to save a mountain on taxes by moving to Switzerland, it had better get ready for an avalanche of criticism.
The drugstore giant could save $4 billion in federal taxes over the next five years by reincorporating in Switzerland, according to a report to be released Wednesday.
The artful tax dodge has been advocated by a cadre of shareholders, including billionaire Barry Rosenstein, who this spring shelled out $147 million for a Hamptons beach house, the highest-ever price tag for a private US residence.
But the move could also cause a major public-relations headache for Walgreen, according to the study compiled by Americans for Tax Fairness, a Washington think tank.
That’s because Walgreen gets nearly a quarter of its revenue from US taxpayer-funded Medicare and Medicaid programs, the report calculates — not to mention millions in federally subsidized bonuses enjoyed by top Walgreen execs.
“Many Americans will find it unfair and deeply unpatriotic if the company moves offshore, while continuing to make its money here, leaving the rest of us to pick up the tab for its tax avoidance,” said Frank Clemente, executive director of the think tank.
The overseas move, known as a “tax inversion,” was a key feature in Pfizer’s recently thwarted $100 billion merger proposal with UK drug giant AstraZeneca.
In the case of Walgreen, it’s being pushed by investors including Rosenstein’s Jana Partners, Och-Ziff and Corvex, who in April met in Paris to discuss the idea with Walgreen brass, including CEO Greg Wasson.
Goldman Sachs Investment Partners also attended the Paris meeting, but the fund isn’t advocating the tax move, said bank spokeswoman Andrea Raphael.
Representatives at the other firms declined to comment.
Walgreen officials didn’t respond to requests for comment. The retailer has recently said it has “no plans” to reincorporate in Europe for tax purposes.
Nevertheless, Walgreen reportedly has been pressured by Italian billionaire Stefano Pessina to try the Swiss tax dodge as it plans to take control of British drugstore chain Alliance Boots.
Walgreen, which bought 45 percent of Alliance Boots in 2012, is expected to complete a merger with the chain next year.
Pessina, chairman of Alliance Boots, already has reincorporated the British chain in Switzerland — a move that spawned picket protests outside London-area Boots drugstores.
If Walgreen attempts a Swiss move, it might spur the same kind of dyspepsia among its own customers, Wednesday’s report suggests, noting that the Illinois-based company has won $46 million in state tax breaks over the past decade.